Piper Sandler analyst Adam Maeder increased the price target for ResMed (NYSE:RMD) to $260 from $252, while keeping a Neutral rating on the stock. Currently trading at $257.65, near its 52-week high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback